35489 membres inscrits Accès abonné revues  Aide   Newsletter    Me connecter
Les Communiqués
 
 
     Nasdaq OMX
 
Rechercher dans le flux Nasdaq GlobeNewswire
Rechercher
Eckert & Ziegler BEBIG: Eckert & Ziegler fait l'acquisition du fournisseur belge d'accessoires de brachythérapie
Fri, 26 08 2016 16:00:00
Communiqué de presse Information réglementée 26 août 2016, 18:00 Seneffe, le 26 août 2016. A compter du 26/08/2016, Eckert & Ziegler BEBIG SA a repris l'ensemble des parts sociales de BrachySolutions BVBA. (...)
Eckert & Ziegler BEBIG: Eckert & Ziegler buys Belgian provider of brachytherapy accessories
Fri, 26 08 2016 16:00:00
Press Release Regulated information 26 August 2016, 06:00 p.m. Seneffe, August 26, 2016. Eckert & Ziegler BEBIG SA took over 100 % of the shares in BrachySolutions BVBA effective August 26, 2016. The company, which is (...)
Medtronic, on Behalf of Its Subsidiary Heartware International, Inc., Announces Offer to Repurchase HeartWare's 3.50% Convertible Senior Notes Due 2017 and 1.75% Convertible Senior Notes Due 2021
Fri, 26 08 2016 12:30:00
DUBLIN - Aug. 26, 2016 - Medtronic plc (NYSE: MDT), on behalf of its indirect, wholly-owned subsidiary HeartWare International, Inc., today announced that, in connection with the completion of the acquisition of HeartWare by (...)
Biotie: BTT1023 receives Orphan Drug Designation in the United States
Fri, 26 08 2016 11:30:00
BIOTIE THERAPIES CORP.     STOCK EXCHANGE RELEASE                  26 August 2016 at 2.30 p.m. (EET) Biotie: BTT1023 receives Orphan Drug Designation in the United States The United States Food and Drug Administration (FDA) has granted (...)
argenx Reports Second Quarter Business Update and Half Year 2016 Financial Results
Fri, 26 08 2016 05:00:00
Successful Phase 1 multiple ascending dose (MAD) study of ARGX-113 in healthy volunteers Phase 2 study in first auto-immune indication planned to start by year-end Cash position strengthened by $40M upfront payment (...)
CORRECTION: Pihlajalinna publishes revised Half Year Financial Report 1 January-30 June 2016 (6 months)
Fri, 26 08 2016 05:00:00
Pihlajalinna Plc     Half Year Financial Report     26 August 2016 at 8.00 a.m. CORRECTION: Pihlajalinna publishes revised Half Year Financial Report 1 January - 30 June 2016 (6 months) Pihlajalinna publishes revised Half Year (...)
uniQure Announces Financial Results For Second Quarter 2016 and Update on Company Progress
Thu, 25 08 2016 20:05:00
~ Progress Across the Pipeline ~ Additional data on AMT-060 in Hemophilia B Expected Later this Year ~Data from Sanfilippo B and Parkinson's Disease Studies Expected in Q1 2017 ~Strong Balance Sheet to Support (...)
FIT Biotech Oy: NOTICE CONVENING AN EXTRAORDINARY GENERAL MEETING OF FIT BIOTECH OY
Thu, 25 08 2016 17:05:00
FIT Biotech Oy Company Release August 25, 2016 at 20.05 pm EET NOTICE CONVENING AN EXTRAORDINARY GENERAL MEETING OF FIT BIOTECH OY The shareholders of FIT Biotech Oy are invited to an extraordinary general (...)
FIT Biotech Oy: FIT Biotech has agreed on a EUR 12,480,000 financing transaction with Bracknor Investment and intends to agree on a EUR 500,000 financing transaction with Sitra
Thu, 25 08 2016 17:00:00
FIT Biotech Oy            Company release            25 August 2016 at 20.00 pm EET FIT Biotech has agreed on a EUR 12,480,000 financing transaction with Bracknor Investment and intends to agree on a EUR 500,000 financing transaction (...)
THE LISTING COMMITTEE OF NASDAQ HELSINKI HAS RESOLVED TO DELIST THE SHARES OF BIOTIE THERAPIES CORP.
Thu, 25 08 2016 11:15:00
BIOTIE THERAPIES CORP.   STOCK  EXCHANGE  RELEASE    25 August 2016, at 2.15 p.m. (EET) THE LISTING COMMITTEE OF NASDAQ HELSINKI HAS RESOLVED TO DELIST THE SHARES OF BIOTIE THERAPIES CORP. The Listing Committee of Nasdaq Helsinki Ltd (...)
Medtronic Reports First Quarter Financial Results
Thu, 25 08 2016 10:45:00
Revenue of $7.2 Billion Decreased 1% as Reported; Prior Year Had Extra Selling Week Revenue Increased Greater than 5 Percent on a Constant Currency, Constant Weeks Basis GAAP (...)
FIT Biotech Oy: FIT Biotech's GMP facility audited and approved - the company resumes manufacturing of drug candidates
Thu, 25 08 2016 06:45:00
FIT BIOTECH OY Company announcement            August 25, 2016 at 9.45 am EET     FIT Biotech's GMP facility audited and approved - the company resumes manufacturing of drug candidates Finnish (...)
AroCell AB: Interim report January - June 2016
Thu, 25 08 2016 06:45:00
Interim report, 1 January - 30 June 2016 Net sales were TSEK 0 (0) Loss after financial items was TSEK -4,804 (-4,046) Earnings per share where SEK -0.17 (-0.17) (...)
Immunicum: Steven Glazer, Charlotte Edenius and Kerstin Valinder Strinnholm proposed as new Board members
Thu, 25 08 2016 06:30:00
Gothenburg, Sweden, August 25, 2016 - The nomination committee of Immunicum AB (publ) proposes that Steven Glazer, Charlotte Edenius and Kerstin Valinder Strinnholm be elected as new Board members at the Annual General Meeting on (...)
Nexstim Plc Terminates Market Making Agreement with Pareto Securities AB in Nasdaq First North Finland
Thu, 25 08 2016 06:00:00
Company announcement, Helsinki, 25 August 2016, at 9:00 am Nexstim Plc (NXTMH:HEX, NXTMS:STO), a medical technology company with a pioneering navigated non-invasive brain stimulation system, has decided to terminate its market (...)
Herantis Pharma Plc's Half year financial report January 1-June 30, 2016 (unaudited)
Thu, 25 08 2016 06:00:00
Herantis Pharma Plc Company release August 25, 2016 at 9:00am Development of Lymfactin® and CDNF proceeds as planned Herantis Pharma Plc's Half year financial report January 1-June 30, 2016 (unaudited) (...)
Zealand's interim report for the first half of 2016 (unaudited)
Thu, 25 08 2016 05:55:47
Company announcement - No. 33 / 2016 Zealand's interim report for the first half of 2016 (unaudited)                - Financial results as expected and in July, the first Zealand invented product was approved in the U.S. (...)
Agfa-Gevaert publishes its second quarter 2016 results - Regulated information - August 25, 2016 - 7:45 a.m. CET
Thu, 25 08 2016 05:45:00
  ·          Overall good performance of the growth engines ·          Recurring EBITDA at 12.1% of revenue in the second quarter and 10.1% after six months - Step towards reaching the 10% full year 2016 target    (...)
Weifa ASA : Record second-quarter revenues and key strategic initiatives
Thu, 25 08 2016 05:30:00
Oslo, 25 August 2016       · Record second-quarter revenues of NOK 95.3 million, a total increase of 35% - organic growth of 17% (excl. Asan)       · Adjusted EBITDA of NOK 18.6 million (12.7) - margin of 19.5% (18.0%) (...)
Novartis announces positive phase III results showing efficacy of BAF312 in patients with secondary progressive MS
Thu, 25 08 2016 05:15:00
The Phase III EXPAND study of BAF312 (siponimod) in secondary progressive multiple sclerosis (SPMS) met its primary endpoint of reducing the risk of three-month confirmed disability progression versus placebo (...)
Targovax ASA: Interim Report second quarter and first half year 2016
Thu, 25 08 2016 05:00:00
Oslo, Norway, 25 August 2016 - Targovax ASA (OSE: TRVX), a clinical stage immuno-oncology company developing targeted immunotherapy treatments for cancer patients, announces its second quarter and first half year 2016 results. A meeting for (...)
IBA SA : IBA Reports Half Year 2016 Results
Thu, 25 08 2016 05:00:00
IBA Reports Half Year 2016 Results Revenues up 20% - On Track To Meet 2016 Guidance Louvain-La-Neuve, Belgium, August 25, 2016 - IBA (Ion Beam Applications S.A., EURONEXT), the world's leading provider of (...)
IBA SA : IBA annonce ses résultats du premier semestre 2016
Thu, 25 08 2016 05:00:00
IBA annonce ses résultats du premier semestre 2016 Revenus en hausse de 20 % - En bonne voie pour réaliser les prévisions 2016 Louvain-La-Neuve, Belgique, le 25 août 2016 - IBA (Ion Beam Applications S.A., (...)
Celyad Reports First Half 2016 Financial Results and Operational Progress
Thu, 25 08 2016 05:00:00
Celyad Reports First Half 2016 Financial Results and Operational Progress Management to Host Conference Call at 2pm CEST/8am EDT Today Mont-Saint-Guibert, Belgium - Celyad (Euronext Brussels and Paris, and NASDAQ: CYAD), a (...)
VALNEVA Announces Signing of Marketing & Distribution Agreement for Seqirus' Flu vaccines Sandovac® and Fluad® in Austria
Thu, 25 08 2016 05:00:00
Valneva Announces Signing of Marketing & Distribution Agreement for Seqirus' Flu vaccines Sandovac ® and Fluad ® in Austria Lyon (France), August 25 , 2016 - Valneva SE ("Valneva" or (...)
publicités
publicité
 
  KauriWeb

Afficher toutes les thématiques